Conclusions: Direct hematogenous dissemination of occult tumor cells may occur in a substantial proportion of patients with early-stage breast cancer. The prognostic implication of the detection of these cells requires long follow-up periods and further studies.
Introduction
Tumor cells can be detected in axillary lymph nodes in 10 -25% of patients with N0 breast cancer after serial sectioning of the lymph nodes [1 -5] and immunohistochemical staining using antibodies against different epithelial markers [1, 4] or RT -PCR [6 -9] , leading to upstaging of the disease.
Several studies have demonstrated that epithelial cells, derived from the initial tumor, can be identified in bone marrow aspirates or/and peripheral blood of patients with breast cancer [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . The malignant origin of these cells was determined by the presence of chromosomal abnormalities, the overexpression of c-erbB2/neu oncogene and their in vitro growth [13, 14, 20] . These occult tumor cells could be identified either immunohistochemically using antibodies against various specific proteins or by RT-PCR assay for the detection of mRNA coding for specific epithelial markers. Large prospective studies have shown that the detection of occult malignant cells represents an independent poor predictive and prognostic factor for disease-free interval and overall survival [12, 14-17, 19, 21] .
The metastatic cascade is known to involve multiple steps. Tumor cells must first penetrate into the vasculature of the primary tumor, survive in the circulation, migrate at other sites, grow in the target organ and, finally, induce angiogenesis [14] . Although this is a rather simplistic and general model of tumor cell dissemination, it seems that in breast cancer the main route of metastatic spread is the lymphatic vasculature, with neoplastic cells first migrating in the regional lymph nodes and then spreading to the blood circulation [5] . However, the incidence of direct hematogenous spread of cancer cells that bypasses the lymphatic vasculature seems to be underestimated in daily clinical practice.
Lymphatic mapping and sentinel lymph node (SLN) biopsy has been introduced as a surgical operation of minimal morbidity that can accurately identify axillary lymph node (ALN)-negative patients and thus spare them the morbidity of axillary lymph nodes dissection [22] [23] [24] . On the other hand, SLN biopsy offers the possibility of a more detailed examination leading to the identification of ALN-positive patients who otherwise would be considered as negative by routine pathologic examination. The SLN is defined as the first node to receive drainage from the tumor; its evaluation could provide a unique opportunity to study the natural history of the disease. Indeed, the evaluation of the status of SLN and ALNs in relation to the presence or absence of occult malignant cells in the peripheral blood or the bone marrow of early-stage breast cancer patients may determine the route of spread of tumor cells in these particular patients.
In order to investigate the incidence of direct hematogenous spread of cancer cells in patients with early stage breast cancer, we studied the presence of occult tumor cytokeratin-19 (CK-19) mRNA + cells in the peripheral blood in relation to the status of SLNs and ALNs. Our hypothesis was that if SLNs and ALNs were negative, then the cancer cells detected in the peripheral blood should have escaped directly into the hematogenous vasculature.
Patients and methods

Patients
One hundred and eleven consecutive patients with clinical stage I or II operable breast cancer were enrolled; a cytologically or histologically confirmed diagnosis of breast adenocarcinoma was required. All patients were operated on by the same surgical team (E.S, J.A. and D.T.) at a single institution during the period 1998-2001. Patients with previous axillary or major breast surgery, multicentric breast cancer and previous radiotherapy to the breast, as well as patients with clinically detectable skin infiltration, were excluded from the study. All patients gave their informed consent to participate in the study and the protocol was approved by the Ethics and Scientific Committees of our Institution.
Detection of SLN
The technical details of SLN identification have been previously reported [25] . In brief, Isosulfan Blue (Patent Blue Violet, Sigma Chemical, St Louis, MO, USA) was used either alone (n = 81) or in combination with nanocolloid (Nanocoll; Amersham, Cygne, Eidhoven, The Netherlands) (n = 30) using intraoperatively hand-held gamma-detector (Navigator GPS; USSC, USA). The SLN was identified the first lymph node to receive the stain. In the case of more than one node with separate afferent lymph nodes, all were marked as SLN. In the case of a block of stained lymph nodes, an effort was made to identify the first draining lymph node among them. If the effort was unsuccessful, the whole block was marked as SLN.
When the probe was used, SLN was identified as the lymph node with an in vivo radioactive count of at least three times that of the background count. If, after the removal of the SLN, the counts of the operative bed were >150% that of the background, the dissection was continued in search of additional SLNs. In all but three patients the SLN biopsy was followed by a level I -II axillary clearance through the same incision.
Sectioning of lymph nodes and histological examination
SLNs were embedded in toto. Those of more than 3 mm in greatest dimension were longitudinally bisectioned through the hilum, and further cut in parallel to the original section so that the thickness of each yielded slice was 2-3 mm. Smaller lymph nodes (up to three) were submitted without previous gross sectioning. Tissue slices were fixed in buffered formalin 10% for up to 24 h, routinely processed and paraffin-embedded. Microscopic tissue sections of 3 mm thickness (on negatively charged SuperFrost Plus glass slides) were obtained from three levels of each paraffin block, separated by 30 mm, and examined after hematoxylin-eosin (H&E) staining and immunostaining as stated below. H&E and immunostaining were performed on adjacent tissue sections. All ALNs identified by palpation of the specimen of the axilla were collected, fixed and further processed as for the SLNs. Micrometastases were considered to be metastatic foci measuring 0.2 -2.0 mm, in greatest diameter, in immunohistochemically stained tissue sections. Smaller foci were characterized as isolated cells (minute micrometastases, micro-micrometastases). Extranodal tissue or vessel infiltrations were not considered as nodal metastases. Metastatic foci in the nodal capsule were accepted as nodal metastases. All histological specimens were evaluated and scored independently by two pathologists (E.N.S. and M.K.)
Immunostaining for CK-19
A monoclonal mouse antihuman CK-19 antibody (DAKO-CK19, Code#M888; DAKO A/S, Glostrup, Denmark) was used at a dilution 1/50 for 60 min, after unmasking by heating for 20 min, in citrate buffer, pH 6, in a microwave oven at 500 W. The immunostaining method applied was a polymer method based on the DAKO EnVision System, Alkaline Phosphatase, Universal (Code#K1396) with Fast Red substrate-chromogen, according to the manufacturer's instructions. Counterstaining was done with hematoxylin (Harris), and coverslipping with an aqueous-based mounting medium (Glycerol, cook # C-0563, Carpinteria, CA). Known positive and negative controls were always used.
Detection of CK-19 mRNA 1 cells in peripheral blood
The method of blood collection, processing and performance of the nested RT-PCR reaction has been previously described in detail [19] . In short, blood samples (10 ml in EDTA) were obtained at the middle of vein puncture to avoid contamination with epidermal epithelial cells and after dilution in phosphate buffered saline (PBS) and centrifugation through Ficoll-Hypaque, total RNA isolation was performed. The isolated RNA was dissolved in diethylpyrocarbonate-treated water and stored at À808C until used. RNA integrity was tested by PCR amplification of the b-actin housekeeping gene. RNA prepared from the MCF-7 and ARH-77 human tumor cell lines, was used as positive and negative control, respectively.
Reverse transcription of RNA was carried out with the Thermoscript RT-PCR system (Gibco). Two different PCR reactions with the respective negative controls were performed with each sample in order to amplify fragments of CK-19 and b-actin. The sequences of primers used (Genset, Paris, France) have been previously reported [19] . These primers extend across at least an intron, so an eventual DNA contamination would not pose a significant problem. The corresponding sizes of PCR products were 745 and 145 bp for CK-19 and b-actin, respectively.
Statistical methods
Continuous variables are expressed as the median value with the range given in parentheses. Comparisons between proportions were made using the Pearson's x 2 statistical test.
Results
Patient characteristics
The characteristics of patients enrolled in the study are presented in Table 1 (Table 5 ).
Discussion
The results of the present study provide interesting information concerning the natural history of breast cancer cell dissemination. Indeed, our data demonstrate that in 31% of the patients with histologically and immunohistochemically negative SLNs and ALNs (N0), occult cancer cells could be detected in the peripheral blood using a sensitive RT-PCR assay able to detect one tumor cell among 10 6 normal peripheral blood mononuclear cells [19] . The detection of CK-19 mRNA + cells in the peripheral blood of these patients was the only indication of dissemination of tumor cells. This is in agreement with clinical data indicating that $ 20 -30% of 
ER, estrogen receptor; Tx, therapy; DFI, disease-free interval; LI, lobular infiltrating tumor.
patients with N0 breast cancer may develop local or distant metastases [26] , suggesting that these patients have occult micrometastatic disease and were understaged. The understaging of N0 breast cancer patients is a well-known phenomenon, since several studies have demonstrated that serial sectioning of routine histology-negative lymph nodes and IHC staining for different epithelial molecules, as well as the use of molecular techniques for mRNA detection of specific markers of malignant cells, may increase the detection rate of micrometastatic involvement in the excised lymph nodes by 9-31% [4 -9] ; subsequently, these cells, through the blood vasculature, can reach distant organs. Indeed, many studies have found that there is a correlation between detection of occult tumor cells in the lymph nodes and metastases [9] . However, this dissemination sequence could not be the case in our patients, since in all N0 patients both SLNs and ALNs were also histologically and immunohistochemically CK-19 negative. Therefore, it is reasonable to hypothesize that the lymphatic spread was not the source of the CK-19 mRNA + cells in the peripheral blood but, most probably, the source was direct invasion of the blood vasculature. Our findings are in agreement with those reported by Relihan et al. [27] , who demonstrated immunohistochemically the presence of occult tumor cells in the bone marrow aspirates obtained from the ribs in two out of 17 breast cancer patients with negative SLNs and ALNs. The SLN is theoretically the first ALN to receive drainage from the tumor and, thus, it should be the first lymph node to be involved by tumor cells. The incidence of CK-19 mRNA + cell detection in the peripheral blood was 29% in patients with SLNs + /ALNs + and 50% in those with SLNs + /ALNs À , a difference that is not statistically significant. Moreover, the relapse rate was similar in the two groups. Previous studies revealed that the detection of occult tumor cells in the bone marrow or the peripheral blood of N + patients also has a poor prognostic value, as does the number of involved lymph nodes [12, 14 -19] . Moreover, these studies have demonstrated that there is no consistent relationship between the detection of occult tumor cells in the bone marrow or the peripheral blood and other commonly used pathological prognostic factors [14 -19] . In one study there was even a significant association of CK-19 positivity by RT-PCR in the blood with distant metastatic versus both node-negative and node-positive disease, but not with any other histopathological parameter examined [28] . patients are more sensitive to chemotherapy and hormone treatment than those observed in N+ patients; such a hypothesis, which is probably related to phenotypic changes of occult tumor cells [29] [30] [31] [32] , is in agreement with the tumor dormancy hypothesis [33, 34] . In addition, we cannot exclude that the tumor burden of patients with N+ disease is significantly higher than that of patients with N0 disease and, therefore, more likely to contain subsets of tumor cells that are resistant to chemotherapy and/or hormone treatment. Therefore, the presented data seem to indicate that there are at least two different subpopulations of occult tumor cells: the first one corresponds to cells that are sensitive to adjuvant chemotherapy and/or hormone treatment and the second one to cells that are resistant to adjuvant treatment. Whether their sensitivity to adjuvant chemotherapy and/or hormone treatment is related to their hematogenous or lymphatic circulation remains an open question. Nevertheless, according to this hypothesis the chemotherapy and hormone treatment resistant tumor cells may switch to an angiogenic phenotype [35, 36] through multiple regulatory factors produced by tumor stromal cells and/or infiltrating blood cells [37] [38] [39] [40] , thus escaping dormancy and leading to clinically evident metastatic disease.
In conclusion, the data reported in the present study clearly indicate that the hematogenous spread of tumor cells in patients with breast cancer may be an early phenomenon occurring before the involvement of the regional ALNs. Adjuvant chemotherapy and hormone treatment might eliminate or decrease the number of occult tumor cells to undetectable levels. Since there is no cure for patients with clinically overt metastases, the only possibility to cure these patients is to try to eliminate occult tumor cells early during the metastatic process, by combining different therapeutic approaches such as chemotherapy, hormones and targeted biological treatments. For this purpose it is important to further understand the mechanisms of tumor cell dissemination and to define specific groups of breast cancer patients who have an increased risk of relapse. 
